• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Can Psilocybin Treat Alcohol Use Disorder?
Research Update

Can Psilocybin Treat Alcohol Use Disorder?

October 31, 2023
Aniruddha Deka, MD
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

Aniruddha Deka, MD. Dr. Deka has no financial relationships with companies related to this material. 

REVIEW OF: Bogenschutz MP et al, JAMA Psychiatry 2022;79(10):953–962

STUDY TYPE: Randomized controlled trial

Over the past decade, there has been great interest in the therapeutic potential of psychedelics. Psilocybin, otherwise known as “magic mushrooms,” has garnered special attention for its potential efficacy in depression, anxiety, end-of-life care, and now alcohol use disorder (AUD).

In this 32-week, double-blind, randomized controlled trial, 95 participants with AUD were randomized to two groups: a psilocybin group (n=49) with a dose of 25–50 mg/70 kg, and an active placebo group (n=46) that received diphenhydramine 25–100 mg. The drugs were administered in two eight-hour sessions at weeks four and eight. Participants also received a total of 12 psychotherapy sessions before, between, and after the two drug administrations. The primary endpoint was percentage of heavy drinking days, which was determined using a self-report technique called the “timeline follow-back method,” and hair and fingernail samples were tested for the alcohol metabolite ethylglucoronide to confirm self-reported abstinence.

The researchers found that over the course of the study, the psilocybin group had a significant reduction in heavy drinking days compared to the diphenhydramine group (9.7% vs 23.6%; p=0.01). The difference was apparent as early as the fifth week, only one week after the first drug administration. Additionally, at 32 weeks, mean daily alcohol consumption was lower in the psilocybin group compared to the diphenhydramine group (1.17 vs 2.26 standard drinks per day; p=0.01). Apart from some minor and transient side effects, psilocybin was well tolerated.

To contextualize this study’s results, meta-analysis found that the number needed to treat (NNT) to prevent heavy drinking with naltrexone was 12 (Jonas DE et al, JAMA 2014;311(18):1889–1900). This means that 12 patients would have to receive naltrexone to prevent one patient from engaging in heavy drinking. The NNT to prevent heavy drinking for psilocybin in this trial was 4.5. 

At first glance, these results seem impressive, but there are some significant limitations to keep in mind. First, outcome measures largely depended on self-reporting, and about half of the participants did not follow up for laboratory confirmation of abstinence. Also, >90% of the participants correctly guessed which intervention they were receiving; adequate blinding remains a challenge for many psychedelic trials. The median household income of the participants was $100,000, which raises questions about generalizability and recruitment bias. And finally, the FDA’s Schedule I restriction means that utilizing psilocybin treatment outside of a research setting is all but impossible, except for a few places (Oregon, and perhaps soon Colorado).

CARLAT TAKE

This study shows some impressive results for psilocybin as a potential new treatment for AUD, albeit with significant study limitations and concerns about generalizability. Though promising, psilocybin remains an investigational treatment that is not ready for prime time just yet. But keep an eye out for future developments; given the enthusiasm for psychedelics, more are sure to come.

Addiction Treatment Research Update
KEYWORDS addiction alcohol use disorder psychedelics
    Aniruddha Deka, MD

    Rapid Initiation of Extended-Release Buprenorphine

    More from this author
    www.thecarlatreport.com
    Issue Date: November 3, 2023
    SUBSCRIBE NOW
    Table Of Contents
    Learning Objectives, Benzodiazepines, CATR, October/November/December 2023
    Benzodiazepines: The Basics and Beyond
    Deprescribing Benzos: A How-To Guide
    When and How Should We Prescribe Benzos?
    Xylazine: An Emerging Threat in the Opioid Overdose Epidemic
    Can Psilocybin Treat Alcohol Use Disorder?
    Perinatal MOUD Use and Infant Discharge to Biological Parents
    CME Post-Test, Benzodiazepines, CATR, October/November/December 2023
    DOWNLOAD NOW
    Featured Book
    • OUDFB1e_Cover_Binding.png

      Treating Opioid Use Disorder—A Fact Book (2024)

      All the tools you need to assess and treat patients struggling with opioid use disorder. 
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2603816031.jpg
      General Psychiatry

      A Scam for Every Woman, Child, and Man: Part 2

      1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.